Elemer Piros
Stock Analyst at Rodman & Renshaw
(3.04)
# 2,391
Out of 4,851 analysts
110
Total ratings
36.54%
Success rate
2.12%
Average return
Main Sectors:
Stocks Rated by Elemer Piros
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BTAI BioXcel Therapeutics | Initiates: Buy | $65 | $1.53 | +4,148.37% | 1 | Mar 19, 2025 | |
| FBLG FibroBiologics | Initiates: Buy | $12 | $0.85 | +1,312.10% | 1 | Dec 12, 2024 | |
| THAR Tharimmune | Initiates: Buy | $17 | $1.58 | +975.95% | 1 | Dec 6, 2024 | |
| QNCX Quince Therapeutics | Initiates: Buy | $11 | $1.09 | +909.17% | 1 | Oct 29, 2024 | |
| MNPR Monopar Therapeutics | Initiates: Buy | $50 | $35.59 | +40.49% | 6 | Oct 11, 2024 | |
| MIRA MIRA Pharmaceuticals | Initiates: Buy | $17 | $1.40 | +1,114.29% | 1 | Sep 30, 2024 | |
| ATHA Athira Pharma | Initiates: Buy | $22 | $0.33 | +6,669.23% | 1 | Aug 19, 2024 | |
| SAVA Cassava Sciences | Reiterates: Buy | $107 | $2.15 | +4,876.74% | 1 | Aug 8, 2024 | |
| CGTX Cognition Therapeutics | Reiterates: Buy | $14 | $0.31 | +4,451.37% | 1 | Jul 2, 2024 | |
| ANVS Annovis Bio | Reiterates: Buy | $67 | $3.24 | +1,967.90% | 1 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $43 | $2.45 | +1,655.10% | 1 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $5.71 | +215.24% | 7 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $7.5 | $1.53 | +390.20% | 3 | Sep 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $15 | $2.47 | +507.29% | 8 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $21 | $7.65 | +174.51% | 8 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $38 | $4.52 | +740.71% | 9 | Aug 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $40 | $0.91 | +4,285.96% | 2 | Jul 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $0.78 | +545.16% | 5 | Jun 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $114 | $8.58 | +1,228.67% | 3 | Jun 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $260 → $200 | $4.02 | +4,875.12% | 6 | Jun 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $23 | $3.41 | +574.49% | 2 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $33 | $12.43 | +165.49% | 3 | Mar 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $40 | $18.51 | +116.10% | 7 | Apr 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $40 | $0.72 | +5,437.10% | 3 | Jan 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $37 | $1.77 | +1,996.32% | 1 | Dec 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $38 → $32 | $4.24 | +654.72% | 2 | Jun 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $77 | $12.26 | +528.06% | 2 | Dec 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $70 | $0.58 | +12,010.73% | 1 | Oct 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $8.47 | - | 5 | Sep 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $24 → $50 | $16.74 | +198.69% | 5 | Nov 19, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $33 | $2.47 | +1,236.03% | 2 | Oct 22, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $9.88 | - | 3 | Jul 11, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $26 | $3.34 | +678.44% | 3 | May 6, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $28 | $132.03 | -78.79% | 1 | Sep 11, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $525 → $850 | $6.44 | +13,098.76% | 1 | Oct 12, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $35 → $21 | $8.40 | +150.15% | 2 | Jul 12, 2017 |
BioXcel Therapeutics
Mar 19, 2025
Initiates: Buy
Price Target: $65
Current: $1.53
Upside: +4,148.37%
FibroBiologics
Dec 12, 2024
Initiates: Buy
Price Target: $12
Current: $0.85
Upside: +1,312.10%
Tharimmune
Dec 6, 2024
Initiates: Buy
Price Target: $17
Current: $1.58
Upside: +975.95%
Quince Therapeutics
Oct 29, 2024
Initiates: Buy
Price Target: $11
Current: $1.09
Upside: +909.17%
Monopar Therapeutics
Oct 11, 2024
Initiates: Buy
Price Target: $50
Current: $35.59
Upside: +40.49%
MIRA Pharmaceuticals
Sep 30, 2024
Initiates: Buy
Price Target: $17
Current: $1.40
Upside: +1,114.29%
Athira Pharma
Aug 19, 2024
Initiates: Buy
Price Target: $22
Current: $0.33
Upside: +6,669.23%
Cassava Sciences
Aug 8, 2024
Reiterates: Buy
Price Target: $107
Current: $2.15
Upside: +4,876.74%
Cognition Therapeutics
Jul 2, 2024
Reiterates: Buy
Price Target: $14
Current: $0.31
Upside: +4,451.37%
Annovis Bio
Jul 2, 2024
Reiterates: Buy
Price Target: $67
Current: $3.24
Upside: +1,967.90%
Jun 21, 2024
Initiates: Buy
Price Target: $43
Current: $2.45
Upside: +1,655.10%
Jun 13, 2024
Initiates: Buy
Price Target: $18
Current: $5.71
Upside: +215.24%
Sep 14, 2023
Maintains: Buy
Price Target: $12 → $7.5
Current: $1.53
Upside: +390.20%
Aug 9, 2023
Reiterates: Buy
Price Target: $15
Current: $2.47
Upside: +507.29%
Aug 4, 2023
Reiterates: Buy
Price Target: $21
Current: $7.65
Upside: +174.51%
Aug 3, 2023
Reiterates: Buy
Price Target: $38
Current: $4.52
Upside: +740.71%
Jul 10, 2023
Reiterates: Buy
Price Target: $40
Current: $0.91
Upside: +4,285.96%
Jun 30, 2023
Reiterates: Buy
Price Target: $5
Current: $0.78
Upside: +545.16%
Jun 20, 2023
Reiterates: Buy
Price Target: $114
Current: $8.58
Upside: +1,228.67%
Jun 20, 2023
Maintains: Buy
Price Target: $260 → $200
Current: $4.02
Upside: +4,875.12%
May 16, 2023
Reiterates: Buy
Price Target: $23
Current: $3.41
Upside: +574.49%
Mar 2, 2023
Reiterates: Buy
Price Target: $33
Current: $12.43
Upside: +165.49%
Apr 14, 2022
Downgrades: Sell
Price Target: $40
Current: $18.51
Upside: +116.10%
Jan 4, 2022
Upgrades: Buy
Price Target: $40
Current: $0.72
Upside: +5,437.10%
Dec 1, 2021
Initiates: Buy
Price Target: $37
Current: $1.77
Upside: +1,996.32%
Jun 30, 2021
Maintains: Buy
Price Target: $38 → $32
Current: $4.24
Upside: +654.72%
Dec 23, 2020
Downgrades: Sell
Price Target: $77
Current: $12.26
Upside: +528.06%
Oct 12, 2020
Initiates: Buy
Price Target: $70
Current: $0.58
Upside: +12,010.73%
Sep 8, 2020
Downgrades: Neutral
Price Target: n/a
Current: $8.47
Upside: -
Nov 19, 2019
Maintains: Neutral
Price Target: $24 → $50
Current: $16.74
Upside: +198.69%
Oct 22, 2019
Assumes: Overweight
Price Target: $33
Current: $2.47
Upside: +1,236.03%
Jul 11, 2019
Upgrades: Overweight
Price Target: n/a
Current: $9.88
Upside: -
May 6, 2019
Initiates: Overweight
Price Target: $26
Current: $3.34
Upside: +678.44%
Sep 11, 2018
Initiates: Overweight
Price Target: $28
Current: $132.03
Upside: -78.79%
Oct 12, 2017
Maintains: Overweight
Price Target: $525 → $850
Current: $6.44
Upside: +13,098.76%
Jul 12, 2017
Maintains: Overweight
Price Target: $35 → $21
Current: $8.40
Upside: +150.15%